{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:09:28Z","timestamp":1778821768393,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cct.2026.108308","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:00:46Z","timestamp":1776286846000},"page":"108308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial"],"prefix":"10.1016","volume":"165","author":[{"given":"Archana","family":"Gopalakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Light","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rawlins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Bertoncelli","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Carballo","family":"De Dios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Increase","family":"Akinyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Klimowska-Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiagarajah","family":"Sasikaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Rothery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Heer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heminder K.","family":"Sokhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","article-title":"Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry","volume":"8","author":"Bangma","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cct.2026.108308_bb0015","series-title":"This Report Was Prepared by Members of the NPCA Project Team","author":"Clarke","year":"2026"},{"issue":"6","key":"10.1016\/j.cct.2026.108308_bb0020","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1016\/j.clgc.2020.05.008","article-title":"Active surveillance for intermediate-risk prostate cancer: systematic review and meta-analysis of current protocols and outcomes","volume":"18","author":"Enikeev","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6","key":"10.1016\/j.cct.2026.108308_bb0025","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.21037\/tau-20-1370","article-title":"Active surveillance for prostate cancer","volume":"10","author":"Shill","year":"2021","journal-title":"Transl. Androl. Urol."},{"issue":"11","key":"10.1016\/j.cct.2026.108308_bb0030","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.cct.2026.108308_bb0035","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JU.0000000000000754","article-title":"Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study","volume":"204","author":"Watson","year":"2020","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2018.02.026","article-title":"Factors influencing mens choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review","volume":"74","author":"Kinsella","year":"2018","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2015.20","article-title":"Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis","volume":"18","author":"Guo","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41391-018-0113-2","article-title":"Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis","volume":"22","author":"Cantiello","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?\u2014a systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108308_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clgc.2020.06.008","article-title":"Accuracy of MRI-guided versus systematic prostate biopsy in patients under active surveillance: a systematic review and meta-analysis","volume":"19","author":"Baccaglini","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"27","key":"10.1016\/j.cct.2026.108308_bb0075","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2026.108308_bb0080","series-title":"Prostate Cancer: Diagnosis and Management","author":"National Institute for Health and Care Excellence (NICE) guideline (NG131)","year":"2021"},{"key":"10.1016\/j.cct.2026.108308_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.cct.2026.108308_bb0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000003788","article-title":"Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial","volume":"211","author":"Mian","year":"2024","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.cct.2026.108308_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging\u2013targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.cct.2026.108308_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2012.9","article-title":"The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy","volume":"24","author":"Sooriakumaran","year":"2012","journal-title":"Int. J. Impot. Res."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bju.13410","article-title":"Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the prostate cancer research international: active surveillance (PRIAS) study","volume":"118","author":"Bokhorst","year":"2016","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.cct.2026.108308_bb0115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.juro.2018.06.013","article-title":"Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort","volume":"200","author":"Marzouk","year":"2018","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2018.10.025","article-title":"Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the movember GAP3 consortium","volume":"75","author":"Van Hemelrijck","year":"2019","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.cct.2026.108308_bb0125","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.23373","article-title":"Active surveillance for early-stage prostate cancer: review of the current literature","volume":"112","author":"Dall\u2019Era","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eururo.2008.06.040","article-title":"Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate Cancer\u2014a review","volume":"54","author":"Van Den Bergh","year":"2008","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0135","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.2012.11295.x","article-title":"Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int."},{"issue":"17","key":"10.1016\/j.cct.2026.108308_bb0140","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cct.2026.108308_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9452","article-title":"Association of Prostate-Specific antigen velocity with clinical progression among African American and non-Hispanic white men treated for low-risk prostate cancer with active surveillance","volume":"4","author":"Nelson","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.urology.2013.09.075","article-title":"A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer","volume":"83","author":"Vickers","year":"2014","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.cct.2026.108308_bb0155","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.cct.2026.108308_bb0160","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.6341","article-title":"Utility of digital rectal examination in a population with prostate cancer treated with active surveillance","volume":"14","author":"Herrera-Caceres","year":"2020","journal-title":"Can. Urol. Assoc. J"},{"issue":"10071","key":"10.1016\/j.cct.2026.108308_bb0165","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.cct.2026.108308_bb0170","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-Cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MOU.0000000000000040","article-title":"Can MRI replace serial biopsies in men on active surveillance for prostate cancer?","volume":"24","author":"Moore","year":"2014","journal-title":"Curr. Opin. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0180","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41391-021-00320-9","article-title":"Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios","volume":"24","author":"Chiam","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0185","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","article-title":"Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial","volume":"75","author":"Klotz","year":"2019","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.cct.2026.108308_bb0190","first-page":"433.e1","article-title":"The role of multiparametric MRI in active surveillance for low-risk prostate cancer: the ROMAS randomized controlled trial","volume":"39","author":"Schiavina","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Invest."},{"issue":"5","key":"10.1016\/j.cct.2026.108308_bb0195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.cct.2026.108308_bb0200","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u2014a report of a European school of oncology task force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0205","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.cct.2026.108308_bb0210","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2021.01.016","article-title":"The importance of being PRECISE in prostate magnetic resonance imaging and active surveillance","volume":"79","author":"Giganti","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.cct.2026.108308_bb0215","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00330-021-08151-x","article-title":"Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance","volume":"32","author":"Sushentsev","year":"2022","journal-title":"Eur. Radiol."},{"issue":"5","key":"10.1016\/j.cct.2026.108308_bb0220","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s00330-020-07336-0","article-title":"MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance","volume":"31","author":"Caglic","year":"2021","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.cct.2026.108308_bb0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euf.2019.03.001","volume":"7","author":"Dieffenbacher","year":"2021","journal-title":"Eur. Urol. Focus"},{"issue":"2","key":"10.1016\/j.cct.2026.108308_bb0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eururo.2025.03.019","article-title":"Magnetic resonance imaging\u2013led risk-adapted active surveillance for prostate cancer: updated results from a large cohort study","volume":"88","author":"Englman","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cct.2026.108308_bb0235","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004559","article-title":"Evolution of active surveillance of prostate cancer: impact of MRI, MRI-guided biopsy and focal therapy","author":"Martin","year":"2025","journal-title":"J. Urol."},{"issue":"11","key":"10.1016\/j.cct.2026.108308_bb0240","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","article-title":"PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI","volume":"34","author":"De Rooij","year":"2024","journal-title":"Eur. Radiol."},{"issue":"7","key":"10.1016\/j.cct.2026.108308_bb0245","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual. Life Res."},{"issue":"3","key":"10.1016\/j.cct.2026.108308_bb0255","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1148\/radiol.2021204321","article-title":"Active surveillance strategies for low-grade prostate cancer: comparative benefits and cost-effectiveness","volume":"300","author":"Kang","year":"2021","journal-title":"Radiology"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:26:44Z","timestamp":1778819204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S1551714426000947"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108308","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108308"}}